+5,232.6%
AZN vs GSK
+939.5%
+4,293.1%
-48.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -1.3% | -0.6% | -1.2% |
| 7D | -3.6% | -3.1% | -0.5% | -1.8% |
| 30D | +9.0% | -0.9% | +9.9% | +9.5% |
| 3M | +11.7% | -4.2% | +15.8% | +14.3% |
| 6M | -2.8% | -1.6% | -1.2% | -2.0% |
| YTD | -1.8% | +2.6% | -4.4% | -3.7% |
| 1Y | +0.9% | +6.2% | -5.4% | -3.1% |
| 3Y | +46.9% | +55.0% | -8.0% | +11.0% |
| 5Y | +73.7% | +42.8% | +30.9% | +35.8% |
| 10Y | +333.0% | +102.1% | +230.8% | +175.7% |
| All | +5,232.6% | +939.5% | +4,293.1% | +1,745.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling